undamentalytics Newsletter
Sign in

Collegium Pharmaceutical, Inc key statistics and ratios

In fiscal 2025, Collegium Pharmaceutical, Inc had return on equity of 23.7%, an operating margin of 23.0%, debt equal to 79.0% of equity and a current ratio of 1.57. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Gross margin87.6%90.9%40.9%34.7%58.0%54.4%45.2%57.5%59.8%59.3%60.0%
Operating margin<−999%−264.9%−7.4%−8.0%18.1%6.4%7.2%29.5%26.9%23.0%19.5%
Net margin<−999%−262.9%−14.0%−7.7%8.6%25.8%−5.4%8.5%11.0%8.1%4.1%
Free-cash-flow margin<−999%−238.8%58.5%7.2%28.5%36.7%26.4%48.4%32.2%42.0%40.6%
Return on equity−69.8%−62.7%−40.0%−25.4%19.6%36.8%−12.6%24.7%32.6%23.7%10.9%
Return on assets−58.1%−50.3%−18.3%−7.6%5.6%10.7%−2.7%4.2%4.9%3.8%1.8%
Asset turnover0.010.191.310.990.650.410.500.490.450.470.43
Current ratio6.204.241.261.271.161.130.971.170.951.571.03
Debt to equity3.1%—12.6%13.2%53.5%69.0%72.3%134.1%103.6%79.0%76.5%
Interest cover (operating income ÷ interest)n/m—n/mn/m1.9x0.8x0.5x2.0x2.3x2.2x2.1x
Effective tax rate————3.0%——36.4%29.8%32.1%11.0%
R&D as % of revenue873.6%30.1%3.1%3.5%3.2%3.4%0.9%0.0%0.0%——
SG&A as % of revenue>999%325.7%45.2%39.2%36.7%43.0%37.1%28.1%33.3%36.5%40.5%
Capital spending as % of revenue27.9%3.5%2.0%2.2%1.8%0.7%0.3%0.1%0.3%0.2%0.2%
Free cash flow ÷ net income————330.4%142.1%—569.6%293.9%521.0%979.5%
Dividends and buybacks ÷ free cash flow—————47.1%11.5%27.3%29.5%7.7%—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 7 checks passed · June 30, 2026
What it owns · $2.1bn
Short-term assets $608mLonger-term assets $1.5bn
What it owes, and who funded it · $2.1bn
Short-term liabilities $590mLonger-term liabilities $1.2bnShareholders' equity $312m
  • Short-term assets cover short-term liabilities $608m of assets due within a year against $590m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $608m short-term assets against $1.2bn of longer-dated liabilities.
  • More cash than debt $129m of cash against $239m of debt.
  • Debt below 40% of shareholders' equity Debt is 77% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 69% to 77% over five years.
  • A year's operating cash flow covers at least 20% of debt $330m of operating cash flow against $239m of debt.
  • Operating profit covers interest at least five times over Operating income of $157m against $76m of interest.

From Collegium Pharmaceutical, Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

48 /100

Moderate moat

How hard Collegium Pharmaceutical's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 5 / 20

    Cash operating profit has been a median 5.4% of total assets over 7 years.

  • Pricing power 14 / 20

    Gross margin has been a median 56.7%, moving by 6.6 percentage points (standard deviation) across 7 years.

  • Durability 2 / 20

    Operating margin has been a median 10.7%; its worst year was -1322.8%.

  • Cash conversion 19 / 20

    Free cash flow was positive in 9 of 10 years, at a median 29.9% of revenue.

  • Discipline 12 / 20

    The diluted share count fell 0.6% over five years; stock-based pay has been a median 5.9% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (53 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: COLL vs CORTCOLL vs SUPNAXSM vs COLL

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Collegium Pharmaceutical, Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Collegium Pharmaceutical, Inc.